- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03833245
Optimizing Pregnancy and Treatment Interventions for Moms 2.0
November 7, 2022 updated by: Jerry Cochran, University of Utah
The US opioid epidemic continues to result in serious health consequences for pregnant and postpartum women.
In the US from 2007 to 2012, an average of 21,000 pregnant women each year reported past month opioid misuse.
This study aims to provide rapid and targeted primary prevention activities aimed at assisting pregnant women with opioid use disorder (OUD) to become linked to and retained in treatment in order to reduce harms to them (including overdose) and their offspring.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Age adjusted rates for overdose among women in the US increased more than six-fold from 1.4 in 1999 to 8.5 in 2016.
Examining Pennsylvania (PA) and Utah (UT; the states where recruitment will happen in this study), these states have some of the highest rates of overdose among women compared to other US states.
Specifically, PA's overdose rate among women surpassed the national average in 2016, and rates of overdose death in UT among women have ranged 2-9 times higher than the national rate between 2009 to 2016.
Both PA and Utah are among the states with the highest opioid prescribing to pregnant women, with Utah being the highest in the nation (41.6%).
Prenatal opioid use disorder (OUD) in the US has brought serious health consequences for mother and infant-including preterm delivery, low birth weight, NAS, and poor breastfeeding, and includes substantial expenditures of health care resources.
Chances for HIV (OR=20.3,
95% CI = 13.8-29.7)
and hepatitis C virus (OR=150.2.
95% CI = 120.9-186.6)
infection among women with OUD are markedly higher than for those without OUD.
Pregnant women with OUD have high rates of psychiatric illnesses, such as depression and anxiety, and other substance use disorders (SUDs), with particularly high rates of smoking (>80%).
Neonatal abstinence syndrome (NAS), an opioid withdrawal syndrome among neonates, has also increased substantially from 3.4/1000 births in 2009 to 5.8/1000 births in 2012.
Poly-substance use among pregnant women with OUD has also been associated with higher levels of needed medications to treat NAS and longer duration of NAS treatment.
Smoking combined with opioid use during pregnancy has likewise been related to longer duration of NAS treatment, greater NAS severity, and higher levels of medication needed to treat NAS symptomology.
Any prenatal opioid use also has been associated with birth defects, including neural tube defects, conoventricular septal defects, atrioventricular septal defects, hypoplastic left heart syndrome, and gastroschisis.
Compared with women without any SUDs, children born to mothers with OUD or OUD plus other SUDs also have been documented to have lower cognitive functioning as they mature.
Problems resulting from illicit and prescription OUD also result in significant social issues.
Pregnant women with OUD have been observed to have financial and housing instability, challenges related to employment, and involvement with the legal system.
Study Type
Interventional
Enrollment (Actual)
106
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Magee Women's Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Adult (≥18 years)
- English speaking
- Pregnant women (pregnancy status verified by gestational age >6 weeks from last menstrual period confirmed by ultrasound)
- OUD verified by examination of medical records for an OUD diagnosis, urine toxicology, and the Diagnostic and Statistical Manual of Mental Disorders (DSM) Checklist (modified from the DSM-IV to confirm current diagnosis for substance use disorders)
- Plan to carry their babies to delivery verified by patient self report
Participant Exclusion Criteria
- Experienced a psychotic or a manic episode in the last 30 days documented in their medical record
- Beyond the 25th week of gestation
- Cannot provide collateral contact information of 2 persons,
- Cannot provide a reliable phone number,
- Plan to move from the area within 2 months of their delivery will or 6 months after not be included in the study
- Inability or unwillingness of subject or legal guardian/representative to give written informed consent.
- Other factors that would cause harm or increased risk to the participant or close contacts, or preclude the participant's full adherence with or completion of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
The standard care condition includes brief case management and referral.
The brief case management involves the participant speaking to a hospital social worker who conducts a patient needs assessment in the areas of behavioral health and social services.
All patients will be referred to MAT and any identified behavioral health or social service needs.
|
|
Experimental: Patient Navigation
The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks.
The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks.
Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.
|
The patient navigation (PN) intervention will initiate following participant recruitment.
It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation.
The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks.
The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks.
Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.
All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid Use Disorder (OUD) and other Substance Use Disorder (SUD) Treatment Linkage/Retention
Time Frame: 36 months
|
OUD and other SUD treatment linkage/retention will be assessed through the treatment services review (TSR-6).
The TSR-6 is a clinically validated 56-item measure with excellent reliability.
We will capture frequency of meetings, sessions, day in OUD and other substance counseling.
|
36 months
|
Opioid Abstinence
Time Frame: 36 months
|
Opioid abstinence will be accessed using a 14-panel urine toxicology screening.
|
36 months
|
Adherence to Medication-Assisted Treatment (MAT)
Time Frame: 36 months
|
Adherence to MAT will be accessed using a 14-panel urine toxicology screening.
|
36 months
|
Adherence to Medication-Assisted Treatment (MAT)
Time Frame: 36 months
|
Adherence to MAT will be assessed through the treatment services review (TSR-6) medication use section.
|
36 months
|
Linkage/Retention in Psychosocial Services
Time Frame: 36 months
|
Linkage/retention in psychosocial services will be accessed through medical record review.
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adequacy of Prenatal Care
Time Frame: 36 months
|
Capturing prenatal care will be accessed through the adequacy of prenatal care utilization index (APNCU).
This index will be used to determine the sufficiency of prenatal care participants received.
|
36 months
|
Needle use and safe sex frequency
Time Frame: 36 months
|
The Risk Behavior Survey (RBA) will be used to access HIV/Hepatitis C virus (HCV) risk behaviors.
The RBA is a self-report, 22-item assessment provides the highest 30-day reliability among standardized instruments for HIV/HCV-risk behaviors among drug users.
|
36 months
|
Incidence of depression and anxiety
Time Frame: 36 months
|
The patient health questionnaire (PHQ) will be used to assess mental health.
The PHQ is an 11-item mental health assessment with demonstrated criterion validity and reliability.
The PHQ accesses depression, suicide ideation, anxiety, somatoform, eating and alcohol use disorders.
|
36 months
|
Child and mother bond following delivery
Time Frame: 36 months
|
Child and mother indicators will be accessed through the Maternal-Fetal Attachment survey.
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bryan MA, Mallik D, Cochran G, Lundahl B. Mindfulness and Savoring: A Commentary on Savoring Strategies and Their Implications for Addiction Treatment. Subst Use Misuse. 2022;57(5):822-826. doi: 10.1080/10826084.2022.2046090. Epub 2022 Mar 10.
- Cochran G, Smid MC, Krans EE, Bryan MA, Gordon AJ, Lundahl B, Silipigni J, Haaland B, Tarter R. A pilot multisite study of patient navigation for pregnant women with opioid use disorder. Contemp Clin Trials. 2019 Dec;87:105888. doi: 10.1016/j.cct.2019.105888. Epub 2019 Nov 12.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 11, 2019
Primary Completion (Actual)
October 1, 2022
Study Completion (Actual)
October 1, 2022
Study Registration Dates
First Submitted
January 28, 2019
First Submitted That Met QC Criteria
February 5, 2019
First Posted (Actual)
February 6, 2019
Study Record Updates
Last Update Posted (Actual)
November 9, 2022
Last Update Submitted That Met QC Criteria
November 7, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 116398
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy Related
-
Helen Keller InternationalEleanor Crook FoundationNot yet recruitingPregnancy Related | Supplementation | Postnatal Related
-
4YouandMeCambridge Cognition Ltd; Sema4; Evidation Health; Vector Institute of Artificial... and other collaboratorsCompletedPregnancy Related | Wearables | Pregnancy EarlyUnited States
-
The University of Texas Health Science Center,...CompletedPregnancy Related | Pregnancy, High RiskUnited States
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Shaare Zedek Medical CenterUnknownPregnancy Related | Pregnancy, High Risk | Anesthesia
-
Atatürk UniversityNot yet recruiting
-
Medical College of WisconsinNot yet recruiting
-
University of PennsylvaniaNot yet recruiting
-
Centre for Infectious Disease Research in ZambiaWellcome Trust; Neopenda, PBCRecruiting
-
Emory UniversityNational Institute of Nursing Research (NINR)Recruiting
Clinical Trials on Patient Navigation
-
University of Colorado, DenverDenver Health and Hospital Authority; Rocky Mountain Human Services; El Grupo...Completed
-
Kaiser PermanenteNational Cancer Institute (NCI); Sea Mar Community Health CentersCompletedColorectal CancerUnited States
-
University of Texas Southwestern Medical CenterCancer Prevention Research Institute of TexasCompletedPrevention Harmful Effects | Compliance Behavior | Non-Small Cell Lung CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRalph Lauren Center for Cancer Care and Prevention; North General Hospital,...CompletedBreast CancerUnited States
-
Northwestern UniversityNortheastern Illinois UniversityRecruiting
-
Renato Cagnacci NetoM.D. Anderson Cancer Center; Eduardo Mondlane University; Hospital Central de... and other collaboratorsNot yet recruitingA Prospective Cohort With Patient Navigation as an Intervention for Breast Cancer Patients (NAVIMOZ)Breast Neoplasm Malignant Primary
-
Horizon Health NetworkRecruitingFrailty | Aging | FractureCanada
-
Medical University of South CarolinaCompletedCancer of Head and NeckUnited States
-
Massachusetts General HospitalCompleted
-
Case Western Reserve UniversityNational Institute of Nursing Research (NINR)CompletedChronic Disease | HIVUnited States